Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
261M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
140M
-
Shares change
-
+5.05M
-
Total reported value, excl. options
-
$402M
-
Value change
-
+$19.2M
-
Put/Call ratio
-
1.47
-
Number of buys
-
61
-
Number of sells
-
-41
-
Price
-
$2.87
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) as of Q1 2024
125 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share as of Q1 2024.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 140M shares
of 261M outstanding shares and own 53.63% of the company stock.
Largest 10 shareholders include FMR LLC (20.1M shares), Avoro Capital Advisors LLC (18.7M shares), RTW INVESTMENTS, LP (18.6M shares), RA CAPITAL MANAGEMENT, L.P. (10.9M shares), VR Adviser, LLC (9M shares), VANGUARD GROUP INC (5.92M shares), MORGAN STANLEY (5.17M shares), BAKER BROS. ADVISORS LP (4M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (3.7M shares), and Artal Group S.A. (3.69M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.